Continuing Medical Education
Gout and hyperuricaemia
Abstract
Gout is the most common crystal arthritis and its prevalence is rising. It is associated with the metabolic syndrome, and hyperuricaemia
may be an independent risk factor for cardiovascular disease. The acute presentation of gout is easily managed, but the underlying cause
is seldom addressed. Indications for initiating uric acid therapy have been clearly established. The classification criteria for gout have been
reviewed and are presented here.
Lifestyle modification is key to the management of gout. The clinician must screen for diabetes, hypertension and hypercholesterolaemia
when the diagnosis of gout is made. The management of asymptomatic hyperuricaemia is still being researched. As yet, there is no indication
to start urate-lowering therapy in such patients. Allopurinol remains the first line of treatment, but there are newer drugs being researched
in various clinical trials. Probenecid is the alternative in patients with preserved renal function, who do not have a history of renal calculi.
Author's affiliations
Mogamat Nur Abrahams, Division of Rheumatology, Department of Medicine, Faculty of Health Sciences, Groote Schuur Hospital and University of Cape Town, and Gatesville Medical Centre, Cape Town, South Africa
Full Text
PDF (69KB)Keywords
Cite this article
Article History
Date published: 2015-11-16
Article Views
Full text views: 3658
Comments on this article
*Read our policy for posting comments here